JP2023539614A - アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物 - Google Patents

アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物 Download PDF

Info

Publication number
JP2023539614A
JP2023539614A JP2023513654A JP2023513654A JP2023539614A JP 2023539614 A JP2023539614 A JP 2023539614A JP 2023513654 A JP2023513654 A JP 2023513654A JP 2023513654 A JP2023513654 A JP 2023513654A JP 2023539614 A JP2023539614 A JP 2023539614A
Authority
JP
Japan
Prior art keywords
methyl
compound
imidazol
isobutylthiophen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539614A5 (https=
JPWO2022049372A5 (https=
Inventor
フェックス，トーマス
オールソン，ベングト
Original Assignee
ヴィコール ファルマ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィコール ファルマ アーベー filed Critical ヴィコール ファルマ アーベー
Publication of JP2023539614A publication Critical patent/JP2023539614A/ja
Publication of JP2023539614A5 publication Critical patent/JP2023539614A5/ja
Publication of JPWO2022049372A5 publication Critical patent/JPWO2022049372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513654A 2020-09-01 2021-09-01 アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物 Pending JP2023539614A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013721.2 2020-09-01
GBGB2013721.2A GB202013721D0 (en) 2020-09-01 2020-09-01 New compounds
PCT/GB2021/052254 WO2022049372A1 (en) 2020-09-01 2021-09-01 Novel compounds for use in the treatment of diseases associated with angiotensin ii

Publications (3)

Publication Number Publication Date
JP2023539614A true JP2023539614A (ja) 2023-09-15
JP2023539614A5 JP2023539614A5 (https=) 2024-09-05
JPWO2022049372A5 JPWO2022049372A5 (https=) 2024-09-05

Family

ID=72749608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513654A Pending JP2023539614A (ja) 2020-09-01 2021-09-01 アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物

Country Status (13)

Country Link
US (1) US20230348444A1 (https=)
EP (1) EP4208460A1 (https=)
JP (1) JP2023539614A (https=)
KR (1) KR20230058467A (https=)
CN (1) CN116568682A (https=)
AU (1) AU2021337193A1 (https=)
CA (1) CA3189240A1 (https=)
CL (1) CL2023000580A1 (https=)
CO (1) CO2023002347A2 (https=)
GB (1) GB202013721D0 (https=)
IL (1) IL300582A (https=)
MX (1) MX2023002522A (https=)
WO (1) WO2022049372A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05140153A (ja) * 1991-05-07 1993-06-08 Merck & Co Inc 置換チオフエンまたはフランを組み込んでいるアンギオテンシンｉｉ拮抗剤
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2013040208A (ja) * 2005-04-12 2013-02-28 Vicore Pharma Ab 新規な三環系アンジオテンシンｉｉアゴニスト

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05140153A (ja) * 1991-05-07 1993-06-08 Merck & Co Inc 置換チオフエンまたはフランを組み込んでいるアンギオテンシンｉｉ拮抗剤
JP2004533457A (ja) * 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2013040208A (ja) * 2005-04-12 2013-02-28 Vicore Pharma Ab 新規な三環系アンジオテンシンｉｉアゴニスト

Also Published As

Publication number Publication date
CO2023002347A2 (es) 2023-05-19
CN116568682A (zh) 2023-08-08
CA3189240A1 (en) 2022-03-10
MX2023002522A (es) 2023-03-13
IL300582A (en) 2023-04-01
AU2021337193A1 (en) 2023-03-23
EP4208460A1 (en) 2023-07-12
WO2022049372A1 (en) 2022-03-10
CL2023000580A1 (es) 2023-10-06
GB202013721D0 (en) 2020-10-14
KR20230058467A (ko) 2023-05-03
US20230348444A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7771049B2 (ja) 新化合物
JP2023539614A (ja) アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物
JP7773988B2 (ja) アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート
US12441718B2 (en) Selective angiotensin II compounds
JP2024511452A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
GB2605148A (en) New compounds
JP2026502510A (ja) 選択的アンジオテンシンｉｉ化合物
JP2024511451A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
JP2024511453A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
HK40081690A (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
HK40081690B (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
CN117222624A (zh) 选择性血管紧张素ii受体配体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415